Clinical trials: Kidney Transplant Immunosuppression
Renal Transplantation
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
- Trial name
- MYFIIRP (NCT00713284)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- California Pacific Medical Center Research Institute
Kidney Transplant; Complications, Immune Suppression
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
Kidney transplant recipients of living- and deceased donor grafts and treated with both mycophenolate mofetil (MMF) and tacrolimus (Tac) will be included.
- Trial name
- MicrobioTac (NCT04207177)
- Testing
- Mycophenolate Mofetil 500 mg Tab, Tacrolimus capsule
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Oslo University Hospital
End Stage Renal Disease, Renal Transplant
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response.
- Trial name
- NCT01154387
- Testing
- Anti-Thymocyte Globulin, TOL101, Steroids
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- Tolera Therapeutics, Inc
Recipients of Liver Transplant
Envarsus XL Immunosuppression Following Liver Transplantation
The standard immunosuppressive regimen for liver transplantation includes twice daily tacrolimus (Prograf). In other transplantation models, there are potential benefits to extended release formulations as lower peak…
- Trial name
- NCT03828058
- Testing
- Envarsus XR, Prograf
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Methodist Healthcare - Memphis
Kidney Disease, Chronic, Transplant Recipient (Kidney)
Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective…
- Conditions
- Kidney Disease, Chronic, Transplant Recipient (Kidney), Immunosuppression
- Trial name
- TRANSPGx (NCT06701825)
- Testing
- Tacrolimus
- Where
- Spain
- Volunteers
- 114 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Renal Impairment, Liver Transplantation
CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of…
- Conditions
- Renal Impairment, Liver Transplantation, Everolimus
- Trial name
- BUILT_01 (NCT01023542)
- Testing
- delayed, low-dose CNI, BU-CNI, BU-Everolimus
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University of Regensburg
Renal Transplant
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation…
- Trial name
- NCT01612299
- Testing
- Zortress® /Everolimus
- Where
- United States
- Sponsor
- University of Kentucky
End Stage Renal Disease
Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation
Kidney transplantation (KT) requires a life-long immune suppression (IS). It has been well-known that long-term IS inevitably causes various complication e.g.
- Trial name
- NCT02199301
- Testing
- Transplantation Conditioning for BMT
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Samsung Medical Center
Kidney Transplant Immunosuppression
Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
The purpose of the study is to identify kidney transplant patients that can be transitioned from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and gene expression as markers of immune…
- Trial name
- NCT04786067
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Kidney Diseases
A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients
Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.
- Trial name
- NCT00407160
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Kidney Transplant, Kidney Transplant Failure and Rejection
(TNX-1500) in Kidney Transplant Recipients
The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
- Conditions
- Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
- Trial name
- TONIX-1500 (NCT07204080)
- Testing
- TNX-1500, Kidney Transplant
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ayman Al Jurdi, MD
Kidney Transplantation
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
Tacrolimus extended release (Astagraf) has recently been approved by the FDA as a once a day dosing regimen. This formulation has the potential to improve compliance.
- Trial name
- Tacrolimus ER (NCT02444143)
- Testing
- tacrolimus extended release
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
Kidney Transplantation, Ischemia-Reperfusion Injury
Thymoglobulin Induction in Kidney Transplant Recipients
The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage that kidneys transplanted from deceased donors…
- Trial name
- TIKT (NCT01239563)
- Testing
- antithymocyte globulin, Basiliximab
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Kidney Transplantation, Immunity
Mucosal Response in Immunocompromised Host
The aim of this study is to verify whether vaccination with Dukoral® (SBL Vaccines) induces an immune response in renal transplant recipients on prednisolone in combination with either a calcineurin inhibitor CNI) or…
- Trial name
- MICH (NCT01109914)
- Testing
- Dukoral
- Where
- Netherlands
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Liver Transplant, Kidney Transplant
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
- Trial name
- PPM - Pro (NCT03527238)
- Testing
- PPM-based Computation Assisted Drug Dosing, Tacrolimus
- Where
- 3 sites in United States, Singapore
- Volunteers
- 62 people
- Sponsor
- University of Florida
Kidney Transplant Rejection
CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
This is a prospective, multi-site, observational study with a matched control group. The primary objective is to evaluate change in renal function over time in recipients of kidney transplants who are undergoing OmniGrafTM…
- Trial name
- CLARITY (NCT05482100)
- Testing
- Patients monitored with OmniGraf testing
- Volunteers
- 500 people
- Sponsor
- Transplant Genomics, Inc.
Renal Transplant Rejection, Transplants and Implants
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
To determine how safe and effective giving Thymoglobulin before transplantation to patients who are going to be receiving kidney transplants.
- Trial name
- NCT00771745
- Testing
- Thymoglobulin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Cincinnati
Kidney Transplant Rejection
AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function
The objective of the proposed study it to perform a pilot clinical trial both to establish feasibility of applying a computational, augmented intelligence based approach, Phenotypic Precision Medicine (PPM), to optimizing…
- Trial name
- AIIM (NCT05432765)
- Testing
- Phenotypic Personalized Medicine Dosing, Standard of Care Dosing
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Florida
Kidney Transplantation
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
- Trial name
- NCT00099736
- Testing
- FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
- Where
- 42 sites in United States
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant, Immunosuppression
KidneyCare Immuno-optimization in Renal Allografts (KIRA)
This is an unblinded, randomized, four-arm interventional research study enrolling patients who are undergoing kidney transplantation.
- Conditions
- Kidney Transplant, Immunosuppression, Allograft
- Trial name
- NCT05423496
- Testing
- KidneyCare, steroid, MMF
- Sponsor
- CareDx